CompletedNot Applicable

Can a Pulmonologist Reliably Assess the Tumor Burden on ROSE Slides Obtained From Pulmonary Nodules and Lymphadenopathy

Italy164 participantsStarted 2019-02-18

Plain-language summary

The study is aimed at verifying if a pulmonologist can reliably assess the tumor burden for the extractive molecular analysis in ROSE samples obtained with endoscopic sampling procedures from intrathoracic lymphadenopathy and pulmonary nodules.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 years * Indication for endoscopic sampling of suspected malignant lymphadenopathy or pulmonary lesion * Written informed consent Exclusion Criteria: * High risk conditions for the performance of bronchoscopy and/or EBUS-TBNA * High risk condition for deep sedation (ASA 4) * Pregnancy

What they're measuring

Accuracy with which a pulmonologist can assess the tumor burden on ROSE slides

Timeframe: The time frame is the duration of each bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for each patient enrolled

Trial details

NCT IDNCT03845764

SponsorMaggiore Bellaria Hospital, Bologna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-06-30

View on ClinicalTrials.gov More Lung Cancer trials